Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes
Sponsor: EndoCell Therapeutics, Inc.
Summary
This study will evaluate the safety, tolerability and efficacy of E-islet 01 in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia
Official title: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of E-islet 01 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2025-08-11
Completion Date
2029-12-31
Last Updated
2025-08-22
Healthy Volunteers
No
Interventions
Allogeneic Human E-islet (E-islet 01)
Allogeneic Human E-islet (E-islet 01), Infused into the hepatic portal vein
Locations (1)
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China